U.S. HBOT Market Report 2026: 1,588 Clinics, Chamber Type Distribution, Pricing & Indications

Last updated: May 2026

TL;DR — U.S. HBOT Market Report 2026

• 1,588 U.S. hyperbaric oxygen therapy centers indexed across 49 states plus DC.
• 59% hard-shell (2.0+ ATA) vs 36% soft-shell (1.3 ATA) of clinics that publish chamber type.
• 15 UHMS-approved indications; Medicare covers a subset under NCD 20.29.
• Data source: hyperbaricfinder.com proprietary clinic directory, refreshed monthly.

State of the U.S. HBOT market in 2026

The U.S. hyperbaric oxygen therapy market in 2026 spans 1,588 clinics across 49 states plus the District of Columbia, with hard-shell medical-grade chambers outnumbering soft-shell wellness chambers roughly 5-to-3 among facilities that disclose chamber type. The category sits inside a U.S. HBOT devices market that Grand View Research valued at $922.2 million in 2024 and projects will reach $1.27 billion by 2030 — a 5.5% CAGR.

Growth is bifurcated. Hospital wound-care programs still anchor reimbursable demand under CMS NCD 20.29, while cash-pay wellness centers using soft-shell chambers drive most of the new-clinic count. Mordor Intelligence pegs the home-care HBOT segment at 9.42% CAGR through 2031 — roughly double the overall market.

The diabetic foot ulcer (DFU) sub-segment is the largest clinical driver. The CDC estimates 1.6 million new DFU cases per year in the U.S. and nearly 80,000 diabetes-related lower-extremity amputations annually, sustaining hospital HBOT referral volume despite mixed long-term efficacy data from the Cochrane review (Kranke et al., 2015). The annual direct medical cost of managing DFUs in the U.S. is estimated at $9 billion, and the annual mortality rate among Medicare DFU patients is roughly 11% — rising to 22% after lower-extremity amputation.

That cost-of-care profile keeps HBOT firmly inside hospital wound-center economics even when the Cochrane evidence is described as "improved healing at 6 weeks but not at 12 months." For payors, the relevant comparator isn't long-term ulcer status — it's amputation avoidance and length-of-hospitalization reduction.

Our directory shows the top 5 states — Texas (57), California (57), New York (47), Florida (43), and Pennsylvania (28) — collectively house 232 clinics, about 33% of all U.S. clinics with a confirmed state assignment. Alaska is the gap state in our index at 5 clinics; we are still verifying whether additional facilities exist there.

Three forces are reshaping U.S. HBOT demand in 2026. First, hospital wound-care programs are adding monoplace capacity to absorb DFU referral volume — Mordor Intelligence notes hospitals still hold 54.85% of end-user share. Second, longevity-focused private clinics are driving most net-new clinic openings, often clustered in metro areas with high disposable income (Dallas, Austin, Scottsdale, Salt Lake City, Newburyport). Third, the home-chamber category is pulling soft-shell volume out of wellness clinics and into direct-to-consumer ownership, a structural threat to the bottom half of the $$ tier.

The regulatory backdrop is tightening. After a cluster of HBOT chamber fires in 2025, the FDA issued a Letter to Health Care Providers in September 2025 reinforcing oxygen-rich-environment safety protocols. Several states are also revisiting cosmetology-board jurisdiction over soft-shell wellness chambers, with Texas and Florida the early movers on tighter inspection rules.

Chamber type distribution: hard-shell vs soft-shell (proprietary data)

Of the 685 U.S. HBOT clinics in our directory that publish chamber type, 59% (405 clinics) operate hard-shell medical-grade chambers capable of 2.0+ ATA, 36% (246 clinics) operate soft-shell mild HBOT chambers limited to roughly 1.3 ATA, and 5% (34 clinics) advertise both. This is the first published cross-sectional split of U.S. HBOT clinics by chamber type.

The distinction is clinically load-bearing. The Undersea & Hyperbaric Medical Society (UHMS) defines hyperbaric oxygen therapy as delivery of 100% oxygen at pressures above 1.4 ATA, and the 15th-edition Indications Manual treatment protocols for the 15 approved conditions require 2.0–3.0 ATA. Soft-shell chambers operating at 1.3 ATA on ambient or concentrated air sit below that threshold and are not cleared for the UHMS indications list.

The FDA has only cleared one soft-sided chamber for medical use — for acute mountain sickness — and warns in its consumer update that other "mild HBOT" marketing claims for conditions like Alzheimer's, autism, and cancer are not approved.

Coverage gap: 903 clinics in our index (57%) don't publish chamber type at all. We resolve this through monthly Outscraper passes and manual verification — coverage improves roughly 3 percentage points per refresh cycle.

The 59/36 split is consistent with two structural facts about the U.S. HBOT market. First, every hospital-based program operates hard-shell chambers because soft-shell can't deliver the UHMS-required 2.0+ ATA. Second, the private wellness category — the fastest-growing segment by clinic count — leans heavily toward soft-shell because the equipment cost is roughly 10x lower ($5,000–$20,000 for a soft-shell vs $80,000–$150,000 for a clinical-grade monoplace hard-shell). That cost asymmetry, combined with looser FDA enforcement of mild HBOT marketing claims, has driven the soft-shell category from near zero a decade ago to 36% of our verified-chamber-type clinics today.

Looking forward, the soft-shell share is likely to grow further as home-chamber sales accelerate at the 9.42% CAGR projected by Mordor Intelligence — pulling marginal volume out of wellness clinics and into individual ownership. Hard-shell hospital programs, by contrast, will grow more slowly but with stickier session economics.

Chamber type comparison table

State-by-state distribution

The top 5 states by HBOT clinic count — Texas, California, New York, Florida, and Pennsylvania — hold ~33% of U.S. clinics with a confirmed state in our index. Texas and California tie at 57 clinics each, reflecting both population scale and a strong concentration of veteran TBI clinics in Texas plus longevity-focused wellness clinics in California.

Per-capita density tells a different story. Utah (16 clinics, ~3.3 million population), Idaho (11 clinics, ~1.9 million), and Hawaii (9 clinics, ~1.4 million) punch well above their population weight, driven by integrative-medicine clinic density and, in Idaho's case, a cluster of cash-pay wellness centers.

A separate 844 clinic records in our master index don't yet have a confirmed state assignment and are excluded from state totals above. They feed monthly verification queues — see Methodology.

UHMS-approved indications and Medicare coverage

The UHMS Hyperbaric Medicine Indications Manual, 15th Edition (2023) lists 15 approved indications for hyperbaric oxygen therapy delivered at 2.0+ ATA with 100% oxygen. CMS National Coverage Determination 20.29 covers a subset of these for Medicare beneficiaries, with the strictest documentation requirements applied to diabetic foot ulcers.

The 15 UHMS-approved indications (2023 update)

1. Air or gas embolism
2. Carbon monoxide poisoning (including CO complicated by cyanide)
3. Clostridial myositis and myonecrosis (gas gangrene)
4. Crush injury, compartment syndrome, and other acute traumatic ischemias
5. Decompression sickness
6. Arterial insufficiencies (including central retinal artery occlusion and selected problem wounds)
7. Severe anemia
8. Intracranial abscess
9. Necrotizing soft tissue infections
10. Refractory osteomyelitis
11. Delayed radiation injury (soft tissue and bony necrosis)
12. Compromised grafts and flaps
13. Acute thermal burn injury
14. Idiopathic sudden sensorineural hearing loss (added 2011, retained in 15th ed.)
15. Avascular necrosis (aseptic osteonecrosis) — newer addition in the 15th-edition update

Medicare coverage (CMS NCD 20.29)

For diabetic foot ulcers — the single largest reimbursable indication by volume — Medicare requires that the patient have type 1 or type 2 diabetes, a lower-extremity wound classified as Wagner grade III or higher, and "no measurable signs of healing for at least 30 days of treatment with standard wound therapy" before HBOT is approved as adjunctive therapy.

Medicare typically authorizes 30–40 sessions, with re-evaluation at every 30 days documenting measurable healing progress. The covered CPT codes are 99183 (physician supervision) and HCPCS G0277 (per-30-minute facility component).

Beyond DFU, NCD 20.29 also explicitly covers acute carbon monoxide poisoning, decompression sickness, gas embolism, gas gangrene, crush injuries and acute traumatic peripheral ischemia, progressive necrotizing infections, acute peripheral arterial insufficiency, preparation/preservation of compromised skin grafts (not for primary management of well-vascularized grafts), chronic refractory osteomyelitis (unresponsive to standard management), osteoradionecrosis, soft-tissue radionecrosis, cyanide poisoning, and actinomycosis (when refractory to penicillin and surgical treatment). NCD 20.29 explicitly excludes topical HBO chamber application and a long list of unapproved uses including multiple sclerosis, cerebrovascular accident, cerebral palsy, organic brain syndrome, autism, and AIDS.

FDA regulatory status

Hyperbaric chambers are FDA-cleared as Class II medical devices through the 510(k) pathway (Product Code CBF). The FDA consumer update "Hyperbaric Oxygen Therapy: Get the Facts" explicitly warns that HBOT has not been cleared for conditions including Alzheimer's, autism, cancer, Lyme disease, cerebral palsy, depression, heart disease, hepatitis, migraine, multiple sclerosis, Parkinson's, spinal cord injury, sports injuries, or stroke — despite widespread off-label marketing.

In September 2025, the FDA reinforced this with a Letter to Health Care Providers after a cluster of fire incidents, emphasizing oxygen-rich-environment safety protocols.

Pricing landscape

U.S. HBOT session prices in 2026 split sharply by chamber type and setting. Soft-shell wellness sessions run $100–$300; private-clinic monoplace hard-shell sessions $200–$400; hospital-based outpatient HBOT for covered indications can exceed $1,500 per session before insurance, though Medicare's national reimbursement averages roughly $596 per session per 2024 Medicare rate data.

Our directory captures 690 clinics with published price tiers. The distribution:

• $$ tier ($150–$300/session): 684 clinics (99% of those that publish) — dominated by soft-shell wellness centers and entry-level cash-pay clinics.
• $$$ tier ($300+/session): 6 clinics — concierge longevity practices and hospital outpatient.
• No published price: 898 clinics (57%) — typical of hospital wound-care programs that bill insurance directly.

The 41% of clinics that don't publish pricing is roughly consistent with the share of HBOT volume routed through hospital systems, which Mordor Intelligence estimates at 54.85% of U.S. HBOT end-user share.

For self-pay patients, a typical 40-session protocol package runs $9,000–$12,000 at independent clinics that offer 20–30% upfront-payment discounts. Medicare beneficiaries with a covered indication typically face $50–$100 per session in copay/coinsurance after Part B deductible.

Geographic pricing variation

Urban-metro pricing varies significantly. Major-metro hospital outpatient programs in San Francisco, New York, and Boston regularly bill $600–$1,200 per session before insurance adjustment. Cash-pay clinics in lower-cost states (Idaho, Utah, Oklahoma) frequently quote $150–$200 per soft-shell session. Florida and Arizona, both heavy on retiree wellness traffic, sit in the middle at $200–$350 for soft-shell, $300–$500 for hard-shell private clinics.

For self-pay patients on a multi-week protocol, the dominant cost lever is the package discount. A clinic quoting $300/session typically offers a 40-session package at $9,000–$10,000 — a 17–25% effective discount. Annual unlimited memberships at biohacker-style wellness clinics range from $4,000 to $12,000 depending on chamber tier and metro.

See our deeper breakdowns in Hyperbaric Oxygen Therapy Cost by State 2026 and HBOT Cost, Insurance & Out-of-Pocket 2026.

Hospital-based vs private clinics

Hospitals account for roughly 55% of U.S. HBOT revenue but a much smaller share of clinic count, because hospital wound-care programs run higher session volumes per facility than private wellness clinics. Our directory's practice_type field is sparse — fewer than 10% of records carry it — so the hospital-vs-private split below relies on secondary research from Mordor Intelligence and Grand View Research.

Hospital-based HBOT programs typically operate UHMS-accredited wound centers with multiplace or monoplace hard-shell chambers, bill insurance and Medicare directly, and concentrate clinically on the 15 UHMS indications — DFU, radiation injury, necrotizing infections. The UHMS Hyperbaric Facility Accreditation program has accredited 267+ facilities in 20 years and is recognized by The Joint Commission.

Private wellness clinics dominate the soft-shell category, operate cash-pay business models targeting longevity, athletic recovery, and off-label conditions, and often combine HBOT with IV therapy, red-light therapy, and other modalities. They drive most net-new clinic openings tracked in our index.

For a deeper side-by-side, see Hospital vs Private HBOT Clinic: Coverage, Cost, and Access 2026.

Two clinic archetypes, two payment models

A typical hospital-based HBOT program operates 2–6 monoplace chambers inside a hospital wound center, runs 4–6 sessions per chamber per day, and bills Medicare/commercial insurance using CPT 99183 plus HCPCS G0277. Average reimbursement per session is in the $500–$700 range. Patient population skews older (Medicare-aged DFU, head-and-neck radiation survivors, refractory osteomyelitis). Average course length runs 30–40 sessions.

A typical private wellness HBOT clinic operates 1–3 soft-shell chambers (occasionally a hard-shell monoplace), runs 4–8 sessions per day, and operates 100% cash-pay. Pricing is $150–$300/session or $9,000–$12,000 for a 40-session package. Patient population skews younger and biohacker-oriented — longevity, athletic recovery, long COVID, traumatic brain injury. Many co-locate with IV therapy, peptides, red-light therapy, and cryotherapy modalities.

The unit economics are very different. Hospital programs need referral volume to justify the capital outlay (a clinical-grade monoplace chamber runs $80,000–$150,000). Private clinics need a recurring cash-pay book and depend on marketing, referrals from concierge physicians, and bundled membership models to keep utilization above breakeven.

Trending indications in 2026

Three off-label indications drive most of the 2026 research and marketing activity in U.S. HBOT: long COVID, traumatic brain injury, and biological aging. None are FDA-cleared or UHMS-approved, but each has at least one peer-reviewed RCT supporting further investigation.

Long COVID

A 2022 Israeli randomized double-blind, sham-controlled trial by the Sagol Center for Hyperbaric Medicine at Shamir Medical Center enrolled 73 patients with post-COVID cognitive symptoms. The HBOT arm (40 sessions, 5 per week, 2.0 ATA) showed significant improvement in global cognitive function, energy, sleep, psychiatric symptoms, and pain interference vs sham; the control arm showed no comparable improvement. A 2024 longitudinal follow-up confirmed durability of effects at one year.

Traumatic brain injury

The Department of Defense launched a new randomized controlled trial in September 2024 (enrollment runs through June 2027) to evaluate HBOT for neurobehavioral symptoms in veterans and service members with mild-to-moderate TBI. The trial is structured as a blinded three-stage group-sequential RCT, designed to resolve mixed findings from prior trials including BIMA, where post-treatment improvements regressed at 6 and 12 months.

Biological aging

The Hachmo et al. 2020 trial published in Aging enrolled 35 adults aged 64+ for 60 daily HBOT sessions. Researchers reported telomere lengthening of up to 38% (B-cells reached 37.63% increase) and a 37% reduction in senescent T-helper cells. The trial was open-label without a sham arm, so causal interpretation is limited, but it has driven significant downstream investment in HBOT-for-longevity clinics.

For a deeper review of TBI evidence specifically, see HBOT for Traumatic Brain Injury: Current Research.

Radiation injury — the strongest off-the-list-but-on-the-list evidence

Among the 15 UHMS-approved indications, delayed radiation injury sits on unusually strong evidence. The Bennett et al. 2016 Cochrane review of 14 trials with 753 participants found moderate-quality evidence that HBOT improves mucosal coverage in osteoradionecrosis (RR 1.3, 95% CI 1.1–1.6, P = 0.003, NNT = 5) and reduces wound breakdown after operative ORN treatment (RR 4.2, 95% CI 1.1–16.8). Single-trial evidence also showed benefit for radiation proctitis. A 2023 Cochrane update by Lin et al. reinforced these findings. Radiation injury isn't a high-volume indication, but for hospitals with head-and-neck oncology programs it's the highest-leverage HBOT referral category.

Autism — the FDA's explicit warning case

The FDA singles out autism in its consumer update as a condition for which HBOT marketing claims are not supported. A 2021 systematic review in pediatric autism HBOT trials concluded none of the 10 literature reviews examined indicated HBOT as clearly effective for autism, and that clinicians cannot recommend it as a safe and scientifically confirmed effective method. Despite this, autism-targeted HBOT marketing remains common in the soft-shell wellness category and is a primary regulatory concern.

How to verify a clinic

Before booking a course of HBOT, consumers should verify three things: chamber type (hard-shell vs soft-shell), facility accreditation status, and insurance/Medicare eligibility for the specific indication being treated. Each takes under 10 minutes.

Chamber type: Ask the clinic whether the chamber operates at 2.0+ ATA with 100% oxygen (medical-grade, hard-shell) or at ~1.3 ATA with ambient air (mild HBOT, soft-shell). Only the former qualifies for UHMS indications and Medicare coverage.

Facility accreditation: Look up the clinic in the UHMS Accredited Facilities Directory. UHMS accreditation is the gold standard and is recognized by The Joint Commission as a Complementary Accrediting organization. A clinic not on the list isn't necessarily unsafe, but accredited facilities have undergone formal safety and clinical-protocol review.

Insurance/Medicare eligibility: Confirm the indication is on the CMS NCD 20.29 covered list and that the clinic bills Medicare/your insurer directly. For diabetic foot ulcer claims, request that the wound be documented at Wagner grade III with 30 days of failed standard care on file before HBOT begins.

Red flags to watch for: Marketing language claiming HBOT treats autism, Alzheimer's, cancer, Lyme disease, multiple sclerosis, or Parkinson's. The FDA has explicitly warned against these claims and reputable clinics will not make them. A clinic that aggressively promotes off-label uses without disclosing the lack of FDA clearance is operating outside professional norms.

Questions to ask before booking:

1. What pressure (ATA) and oxygen concentration does your chamber operate at?
2. Are you UHMS-accredited? If not, who oversees safety protocols?
3. Who is the supervising hyperbaric physician, and are they UHMS or ABPM-certified in undersea/hyperbaric medicine?
4. Can you provide written documentation of FDA 510(k) clearance for the chamber model in use?
5. What's your protocol for emergency depressurization, and when was the last fire-safety inspection?

For a printable checklist version, see Hyperbaric Oxygen Therapy Safety Checklist: Red Flags and What to Verify 2026 and 15 Questions to Ask Before Starting HBOT 2026.

FAQ

How many HBOT clinics are in the U.S.?

There are 1,588 hyperbaric oxygen therapy clinics indexed in the U.S. as of May 2026, distributed across 49 states plus the District of Columbia. The count combines hospital-based wound-care programs (roughly 55% of session volume) and private wellness clinics (the larger share of net-new openings). This figure is maintained by hyperbaricfinder.com via monthly Outscraper passes plus manual verification — 510 clinics (32%) are verified entries with confirmed contact details. Alaska, with five indexed clinics, is the smallest covered state and may have additional facilities still under verification.

What's the difference between hard-shell and soft-shell HBOT?

Hard-shell HBOT chambers are rigid steel or acrylic enclosures that pressurize to 2.0–3.0 ATA with 100% oxygen — the standard required for the 15 UHMS-approved indications and for Medicare coverage. Soft-shell chambers (often called "mild HBOT" or mHBOT) are fabric/nylon enclosures pressurized to roughly 1.3 ATA with ambient or concentrated air, well below the UHMS-defined 1.4 ATA threshold for hyperbaric oxygen therapy. The FDA has cleared one soft-sided chamber for acute mountain sickness only. Among our 685 clinics that publish chamber type, 59% are hard-shell, 36% are soft-shell, and 5% offer both.

Does Medicare cover HBOT?

Yes, but only for a subset of UHMS indications under CMS NCD 20.29. The largest covered indication by volume is diabetic foot ulcer, which requires: (1) type 1 or type 2 diabetes, (2) lower-extremity wound at Wagner grade III or higher, and (3) documented failure of at least 30 days of standard wound care. Medicare typically authorizes 30–40 sessions with 30-day reassessments. CPT 99183 covers physician supervision and HCPCS G0277 covers each 30-minute facility increment. Off-label uses — long COVID, TBI, anti-aging — are not covered.

What conditions are FDA-approved for HBOT?

The FDA clears hyperbaric chambers as Class II devices through the 510(k) process for 13+ specific conditions that overlap with the UHMS indications list, including air/gas embolism, carbon monoxide poisoning, decompression sickness, gas gangrene, necrotizing soft-tissue infections, acute traumatic ischemias, severe anemia, intracranial abscess, refractory osteomyelitis, delayed radiation injury, compromised grafts and flaps, acute thermal burns, and idiopathic sudden sensorineural hearing loss. The FDA explicitly warns that HBOT is not cleared for Alzheimer's, autism, cancer, Lyme disease, depression, heart disease, multiple sclerosis, Parkinson's, or stroke.

How much does HBOT cost in 2026?

U.S. HBOT session costs in 2026 range from $100 at low-end soft-shell wellness centers to over $1,500 at hospital outpatient programs for covered indications. The median private-clinic monoplace hard-shell session is approximately $250, with most cash-pay clinics in the $150–$400 range. Medicare's national average reimbursement is roughly $596 per session. A typical 40-session protocol runs $9,000–$12,000 at independent clinics, often with 20–30% upfront-payment discounts. Medicare beneficiaries pay $50–$100 per session in copay/coinsurance after the Part B deductible. In our directory, 99% of clinics that publish pricing fall in the $$ tier ($150–$300).

Which states have the most HBOT clinics?

The top 5 states by HBOT clinic count in 2026 are Texas (57), California (57), New York (47), Florida (43), and Pennsylvania (28) — collectively 232 clinics, or 33% of U.S. clinics with confirmed state assignment. Texas and California are tied at #1, reflecting both population scale and regional clusters: veteran TBI clinics concentrate in Texas, while longevity wellness clinics concentrate in California. On a per-capita basis, Utah (16), Idaho (11), and Hawaii (9) outperform their population share. Alaska is the smallest indexed state at 5 clinics and may have additional facilities under verification.

Is HBOT effective for long COVID?

Evidence is promising but not yet sufficient for FDA approval or Medicare coverage. The Shamir Medical Center 2022 randomized double-blind sham-controlled trial of 73 patients with post-COVID cognitive symptoms showed significant improvement in global cognitive function, energy, sleep, psychiatric symptoms, and pain interference after 40 sessions at 2.0 ATA — with effects durable at one-year follow-up. A 2024 prospective registry of 232 patients reinforced the finding. Multiple U.S. RCTs are now enrolling. Long COVID HBOT is currently cash-pay only, typically $250–$400 per session for a 40-session course.

How do I find a UHMS-accredited HBOT center?

Use the UHMS Accredited Facilities Directory, which lists 267+ facilities that have completed UHMS Hyperbaric Facility Accreditation — the only hyperbaric-specific accreditation recognized by The Joint Commission as a Complementary Accrediting organization. Accreditation reviews cover chamber safety, staff training, clinical protocols, and emergency procedures. A clinic absent from the directory isn't necessarily unsafe, but accredited facilities have undergone formal third-party review. For consumers, UHMS accreditation is the single highest-leverage signal of clinical credibility. Pair the UHMS lookup with our chamber-type filter at hyperbaricfinder.com to find an accredited hard-shell facility in your state. Note: the majority of UHMS-accredited facilities are hospital-based wound-care programs; a private wellness clinic that holds UHMS accreditation is rare and signals serious clinical investment.

What's the difference between mild and medical-grade HBOT?

"Medical-grade HBOT" refers to hard-shell chambers pressurized to 2.0–3.0 ATA with 100% oxygen — the standard required for the 15 UHMS-approved indications, Medicare reimbursement, and most peer-reviewed clinical research. "Mild HBOT" (mHBOT) refers to soft-shell chambers pressurized to roughly 1.3 ATA with ambient or concentrated air, sitting below the UHMS-defined 1.4 ATA threshold for hyperbaric oxygen therapy. Mild HBOT is FDA-cleared only for acute mountain sickness; the FDA explicitly warns against marketing it for other conditions. Hard-shell is the right choice for any covered indication; soft-shell may be appropriate for wellness applications where consumers understand it isn't medical HBOT.

What's the average wait time at a UHMS-accredited hospital HBOT program?

Wait times vary widely. Hospital wound-care programs treating Medicare diabetic foot ulcer patients typically schedule within 1–2 weeks once the Wagner grade III documentation and 30-day standard-care failure record are confirmed. Hospital programs for emergent indications (carbon monoxide poisoning, air embolism, gas gangrene) treat on a same-day basis. Private cash-pay clinics, including most soft-shell wellness centers, generally book within 1–3 days. The 510 verified entries in our directory include current contact information for booking inquiries; we don't yet publish wait-time data systematically but are piloting collection in Q3 2026.

Methodology

This report draws on hyperbaricfinder.com's proprietary clinic directory of 1,588 U.S. HBOT facilities, refreshed monthly via Outscraper Google Maps data extraction plus manual verification by our editorial team. Each record includes name, address, state, city, chamber type (where published), price tier, and verification status. 510 entries (32%) are flagged "verified" — meaning a member of our team confirmed contact details and chamber type within the last 90 days.

Chamber-type classification is based on the clinic's own public-facing marketing language. We classify a clinic as "hard-shell" when it advertises 2.0+ ATA or 100% oxygen delivery, "soft-shell" when it advertises 1.3 ATA mild HBOT, and "both" when both protocols are explicitly listed. 903 clinics (57%) don't publish enough information to classify and are excluded from the chamber-type denominator (n=685).

Price tier is similarly self-reported. The $$ tier corresponds to roughly $150–$300/session, $$$ to $300+/session. 898 clinics (57%) don't publish pricing and are excluded from price distribution figures.

Refresh cadence: Full directory refresh runs monthly; verification queue runs continuously. Major regulatory updates (CMS NCD changes, UHMS Indications Manual revisions, FDA guidance) trigger an out-of-cycle report update.

Report inaccuracy: If you spot a clinic listing error, an outdated chamber-type classification, or a regulatory fact that needs correction, email corrections@hyperbaricfinder.com. We typically resolve flagged inaccuracies within five business days.

Limitations: Our practice_type field (hospital vs private clinic) is populated for fewer than 10% of records; hospital-vs-private market share figures in this report rely on secondary research from Grand View Research and Mordor Intelligence. State-level totals exclude 844 records still pending state confirmation. The avg_rating field is statistically thin and should not be used for state-by-state comparison.

Key findings at a glance

For citation and reference, the headline numbers from this report:

• 1,588 U.S. HBOT clinics indexed nationwide (May 2026).
• 49 states + DC covered; Alaska under verification for additional facilities.
• 59% hard-shell vs 36% soft-shell vs 5% both — of 685 clinics that publish chamber type.
• 903 clinics (57%) don't publish chamber type.
• 510 clinics (32%) are verified entries with confirmed contact details.
• Top 5 states: TX (57), CA (57), NY (47), FL (43), PA (28) — 33% of clinics with confirmed state.
• 15 UHMS-approved indications per the 2023 Hyperbaric Medicine Indications Manual, 15th Edition.
• CMS NCD 20.29 covers HBOT for diabetic foot ulcers at Wagner grade III with 30-day failed standard care.
• $596 national average Medicare reimbursement per HBOT session (2024 data).
• $100–$300 typical self-pay range for soft-shell wellness session in 2026.
• $250–$1,500+ range for hard-shell private clinic / hospital outpatient session.
• $9,000–$12,000 typical 40-session protocol package at independent clinics.
• 267+ UHMS-accredited facilities recognized by The Joint Commission.
• $922.2M U.S. HBOT devices market 2024 → $1.27B projected 2030 (5.5% CAGR, Grand View).
• 9.42% CAGR home-care HBOT segment through 2031 (Mordor Intelligence).
• 1.6 million new U.S. DFU cases per year; 80,000 diabetes-related lower-extremity amputations annually (CDC).

About this report: The U.S. HBOT Market Report is produced quarterly by the hyperbaricfinder.com editorial team using our proprietary directory of 1,588 U.S. HBOT clinics. The dataset is refreshed monthly via Outscraper Google Maps extraction plus manual editorial verification. Cite as: "hyperbaricfinder.com U.S. HBOT Market Report 2026." For data partnerships, custom segmentation, or to flag a clinic listing correction, contact corrections@hyperbaricfinder.com.

The next quarterly update (August 2026) will include: state coverage closure for the 844 records currently pending state assignment, an expanded hospital-vs-private practice-type field, the first per-capita clinic-density index by metro, and updated chamber-type coverage targeting 50% disclosure rate (up from 43% today).